Drug interaction evaluation of the novel phosphodiesterase type 5 inhibitor tunodafil (youkenafil): Effects of tunodafil on omeprazole pharmacokinetics based on CYP2C19 gene polymorphism, and effects of ritonavir on tunodafil pharmacokinetics - Wang, Keli; Ding, Juefang; Cheng, Minlu; Li, Xianjing; Zhou, Huan; Song, Qinxin; Yang, Yuanxun; Li, Juan; Ding, Li (European journal of pharmaceutical sciences, 2025)
Keywords: Adult; CYP2C19 polymorphism; Cytochrome P-450 CYP2C19 - genetics; Cytochrome P-450 CYP2C19 - metabolism; Cytochrome P-450 CYP2C19 Inhibitors - pharmacology; Drug Interactions; Drug-drug interaction; Female; Humans; Imidazoles - pharmacokinetics; Imidazoles - pharmacology; Male; Microsomes, Liver - drug effects; Microsomes, Liver - metabolism; Middle Aged; Omeprazole; Omeprazole - blood; Omeprazole - pharmacokinetics; Pharmacokinetics; Phosphodiesterase 5 Inhibitors - pharmacokinetics; Phosphodiesterase 5 Inhibitors - pharmacology; Polymorphism, Genetic; Ritonavir; Ritonavir - pharmacology; Tunodafil (youkenafil); Young Adult; Omeprazole; CYP2C19 polymorphism; Drug-drug interaction; Pharmacokinetics; Ritonavir; Tunodafil (youkenafil)